Summary of Biomarker Analysis
Method of Measurement
Biomarker Measured
Biomarker Categories
Summary completed October 2019
Biomarkers for Alzheimer’s Disease
BiomarkerEEG Connectivity and Graph Theory Combined With ApoE Testing |
Biomarker MeasuredImaging |
Method of MeasurementCell signaling |
UseSusceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerMicroRNA and Protein expression |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementCell signaling |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerElectroencephalography (EEG) (during memory tasks) |
Biomarker MeasuredImaging |
Method of MeasurementCell signaling |
UseSusceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerMulti-modal Neuroimaging |
Biomarker MeasuredBlood/Plasma, Imaging, CSF |
Method of MeasurementAmyloid |
UseDiagnostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerCSF1 R (MIcroglial Colony Stimulating Factor-1 Receptor) |
Biomarker MeasuredBlood/Plasma, CSF |
Method of MeasurementInflammation |
UsePharmacodynamic/response |
Stage of DevelopmentClinical trials |
BiomarkerCSF1 R (MIcroglial Colony Stimulating Factor-1 Receptor) |
Biomarker MeasuredBlood/Plasma, CSF |
Method of MeasurementInflammation |
UsePharmacodynamic/response |
Stage of DevelopmentClinical trials |
BiomarkerCirculatory MicroRNAs (miRNAs) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementCell signaling |
UseUnknown |
Stage of DevelopmentPreclinical |
BiomarkerCholinergic Markers (CHOLINE) |
Biomarker MeasuredCSF |
Method of MeasurementCell signaling |
UsePharmacodynamic/response, Predictive |
Stage of DevelopmentClinical trials |
BiomarkerMulti-parameter Diagnostic Blood Test (RH-VAL) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementUnknown |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerCerebrovascular reactivity to carbon dioxide (CVR CO2) |
Biomarker MeasuredDoppler ultrasonography |
Method of MeasurementVasculature |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerCeramides |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementInflammation |
UseDiagnostic |
Stage of DevelopmentClinical trials |
BiomarkerNasal Swabs and Voice Dysfunction |
Biomarker MeasuredOther bodily fluids |
Method of MeasurementAmyloid, Tau |
UseDiagnostic, Monitoring |
Stage of DevelopmentClinical trials |
BiomarkerBrain-derived neurotrophic factor (BDNF) |
Biomarker MeasuredBlood/Plasma, Generic |
Method of MeasurementGenetic variation/DNA, Neuronal damage |
UseDiagnostic, Monitoring |
Stage of DevelopmentClinical trials |
BiomarkerNeocortical β-amyloid burden (NAB) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementAmyloid |
UseSusceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerBlood brain barrier (BBB) |
Biomarker MeasuredBlood/Plasma, Imaging, CSF |
Method of MeasurementVasculature |
UseDiagnostic, Monitoring |
Stage of DevelopmentClinical trials |
BiomarkerNeuraCeq (florbetaben f 18 injection) |
Biomarker MeasuredImaging |
Method of MeasurementAmyloid |
UseDiagnostic |
Stage of DevelopmentIn use (FDA approved) |
BiomarkerBlood biomarker for mtDNA Damage |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementGenetic variation/DNA |
UseDiagnostic, Monitoring |
Stage of DevelopmentClinical trials |
BiomarkerNeurogranin |
Biomarker MeasuredCSF |
Method of MeasurementNeuronal damage |
UseDiagnostic, Susceptibility/risk |
Stage of DevelopmentClinical trials |
BiomarkerBAY 94-9172 (Florbetaben) |
Biomarker MeasuredBlood/Plasma, Imaging |
Method of MeasurementAmyloid |
UseMonitoring, Pharmacodynamic/response |
Stage of DevelopmentClinical trials |
BiomarkerNeuronal pentraxin 1 (NP1) |
Biomarker MeasuredBlood/Plasma |
Method of MeasurementNeuronal damage |
UseDiagnostic |
Stage of DevelopmentClinical trials |
Questions? Additional biomarkers to share? Contact Us